Stay updated on Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page.

Latest updates to the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page
- Check3 days agoChange DetectedRevision updated to v3.5.3, replacing the previous v3.5.2. This represents a minor documentation/versioning update and does not change study details or eligibility content.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision label updated to v3.5.2; the v3.5.0 label was removed. This is a routine site maintenance update and does not affect the study content or user-facing information.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedThe page version was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision: v3.4.3 was added, replacing the previous v3.4.2.SummaryDifference0.0%

- Check81 days agoChange DetectedRevision label updated to v3.4.2 and the prior funding-status notice was removed; these are site-wide maintenance updates that do not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check88 days agoChange DetectedAdded a government funding lapse notice with links to cc.nih.gov and opm.gov for status updates. Updated the page revision stamp to v3.4.1, replacing the prior v3.4.0.SummaryDifference0.4%

Stay in the know with updates to Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page.